Probabilities of Eventually Developing or Dying of Cano

Ca-A Cancer Journal for Clinicians 35, 36-56

DOI: 10.3322/canjclin.35.1.36

Citation Report

#	Article	IF	CITATIONS
1	The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids, 1984, 44, 467-484.	0.8	60
2	Breast Models: A Useful Tool for Instruction. Occupational Health Nursing, 1985, 33, 513-514.	0.2	2
3	The Probability of Dying of Injuries by the Year 2000. JAMA - Journal of the American Medical Association, 1985, 254, 3350.	3.8	8
4	Evaluation of nonpalpable breast lesions. American Journal of Surgery, 1986, 151, 467-469.	0.9	20
5	Epidemiology in risk assessment for regulatory policy. Journal of Chronic Diseases, 1986, 39, 1157-1168.	1.3	8
6	OCCULT-BLOOD SCREENING. Lancet, The, 1986, 328, 109-110.	6.3	О
7	Hereditary predisposition to cancer: Opportunities for early detection and intervention. Seminars in Oncology Nursing, 1986, 2, 176-183.	0.7	2
8	Changing trends of tobacco use in a teenage population in western Pennsylvania American Journal of Public Health, 1986, 76, 196-197.	1.5	33
9	Phase I and II Agents in Cancer Therapy: I. Anthracyclines and Related Compounds. Journal of Clinical Pharmacology, 1986, 26, 491-509.	1.0	36
10	Breast Cancer Risk Analysis. Archives of Surgery, 1986, 121, 973.	2.3	1
10	Breast Cancer Risk Analysis. Archives of Surgery, 1986, 121, 973.  What are the odds that smoking will kill you?. American Journal of Public Health, 1987, 77, 425-431.	2.3	219
11	What are the odds that smoking will kill you?. American Journal of Public Health, 1987, 77, 425-431.  An alternative to the magic bullet paradigm for specific cancer therapy. Medical Hypotheses, 1987, 24,	1.5	219
11	What are the odds that smoking will kill you?. American Journal of Public Health, 1987, 77, 425-431.  An alternative to the magic bullet paradigm for specific cancer therapy. Medical Hypotheses, 1987, 24, 43-51.	0.8	219
11 12 13	What are the odds that smoking will kill you? American Journal of Public Health, 1987, 77, 425-431.  An alternative to the magic bullet paradigm for specific cancer therapy. Medical Hypotheses, 1987, 24, 43-51.  The Probability of Cancer Death in Italian Males and Females. Tumori, 1987, 73, 91-97.	0.8 0.6	219 5 0
11 12 13	What are the odds that smoking will kill you?. American Journal of Public Health, 1987, 77, 425-431.  An alternative to the magic bullet paradigm for specific cancer therapy. Medical Hypotheses, 1987, 24, 43-51.  The Probability of Cancer Death in Italian Males and Females. Tumori, 1987, 73, 91-97.  Statistical and epidemiologic data on urologic cancer. Cancer, 1987, 60, 692-717.	0.8 0.6 2.0	219 5 0
11 12 13 14	What are the odds that smoking will kill you? American Journal of Public Health, 1987, 77, 425-431.  An alternative to the magic bullet paradigm for specific cancer therapy. Medical Hypotheses, 1987, 24, 43-51.  The Probability of Cancer Death in Italian Males and Females. Tumori, 1987, 73, 91-97.  Statistical and epidemiologic data on urologic cancer. Cancer, 1987, 60, 692-717.  Laryngeal carcinoma in black patients. Cancer, 1988, 61, 167-172.  Phase II evaluation of sequential hepatic artery infusion of 5-fluorouracil and hepatic irradiation in	0.8 0.6 2.0 2.0	219 5 0 62 12

#	Article	IF	Citations
19	Carcinogenic risk estimation. Science, 1988, 240, 1043-1047.	6.0	28
20	Role of sigmoidoscopy in screening for colorectal cancer: A critical review. Gastroenterology, 1988, 95, 492-499.	0.6	71
21	Skin Types in Dysplastic Nevus Syndrome. The Journal of Dermatologic Surgery and Oncology, 1988, 14, 827-831.	0.8	13
22	Use of Risk Factors in Counseling Patients. Hematology/Oncology Clinics of North America, 1989, 3, 599-610.	0.9	4
23	Lifetime Risks of Hip, Colles', or Vertebral Fracture and Coronary Heart Disease Among White Postmenopausal Women. Archives of Internal Medicine, 1989, 149, 2445.	4.3	532
24	Spatial clustering of multiple hyperplastic, adenomatous, and malignant colonic polyps in individual patients. Diseases of the Colon and Rectum, 1989, 32, 641-652.	0.7	52
25	Breast cancer risk: A review of definitions and assessments of risk. Journal of Surgical Oncology, 1989, 41, 42-46.	0.8	7
26	Converting relative risks to absolute risks: A graphical approach. Statistics in Medicine, 1989, 8, 641-651.	0.8	41
27	Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Human Pathology, 1989, 20, 723-725.	1.1	99
28	Endoscopic Screening and Surveillance for Gastrointestinal Malignancy. Surgical Clinics of North America, 1989, 69, 1205-1225.	0.5	15
29	Screening for Colorectal Cancer. Annals of Internal Medicine, 1990, 113, 373.	2.0	545
30	Screening for Cervical Cancer. Annals of Internal Medicine, 1990, 113, 214.	2.0	483
31	The prostate: An increasing medical problem. Prostate, 1990, 16, 39-48.	1.2	321
32	Family history and the risk of prostate cancer. Prostate, 1990, 17, 337-347.	1.2	609
33	Medical and legal implications of screening and follow-up procedures for breast cancer. Cancer, 1990, 66, 1351-1362.	2.0	37
34	Magnitude and time trends of the life-time risk of developing cancer in Saarland, Germany. European Journal of Cancer & Clinical Oncology, 1990, 26, 978-982.	0.9	4
35	Conservative management of breast fibroadenomas. American Journal of Obstetrics and Gynecology, 1991, 164, 1647-1651.	0.7	20
36	Prospective Followâ€Up for Malignant Melanoma in Patients with Atypicalâ€Mole (Dysplasticâ€Nevus) Syndrome. The Journal of Dermatologic Surgery and Oncology, 1991, 17, 44-48.	0.8	84

#	ARTICLE	IF	CITATIONS
37	Colonoscopic Surveillance after Polypectomy: Considerations of Cost Effectiveness. Annals of Internal Medicine, 1991, 114, 177-182.	2.0	94
38	Prostate Cancer: Comparison of Digital Rectal Examination and Transrectal Ultrasound for Screening. Journal of Urology, 1991, 145, 86-90.	0.2	41
39	Cost Effectiveness of Colorectal Cancer Screening in the Elderly. Annals of Internal Medicine, 1991, 115, 807-817.	2.0	111
40	Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin. Ca-A Cancer Journal for Clinicians, 1991, 41, 201-226.	157.7	192
41	Epidemiology of large bowel cancer. World Journal of Surgery, 1991, 15, 562-567.	0.8	33
42	Screening for Colorectal Cancer. New England Journal of Medicine, 1991, 325, 37-41.	13.9	186
43	Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA ??88) on the Incidence of Invasive Cervical Cancer. Medical Care, 1992, 30, 1067-1082.	1.1	19
44	Early detection of prostate cancer. Human Pathology, 1992, 23, 211-222.	1.1	253
45	Estimates of costs and effects of screening for colorectal cancer in the united states. Cancer, 1992, 70, 1288-1295.	2.0	39
46	Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 1993, 71, 933-938.	2.0	707
47	Risk factors for breast cancer development. Cancer, 1993, 71, 2127-2140.	2.0	81
48	Perceptions of colorectal cancer in a socioeconomically disadvantaged population. Journal of Community Health, 1993, 18, 347-362.	1.9	68
49	Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy. New England Journal of Medicine, 1993, 328, 1237-1243.	13.9	523
50	Synchronous Adenocarcinoma and Transitional Cell Carcinoma of the Bladder Associated with Augmentation: Case Report And Review of the Literature. Journal of Urology, 1993, 149, 115-118.	0.2	51
51	Mass Colorectal Cancer Screening. AAOHN Journal, 1993, 41, 186-191.	0.5	0
52	Surrogate markers in aids and cancer trials. Statistics in Medicine, 1994, 13, 1423-1435.	0.8	108
53	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate, 1994, 25, 249-265.	1.2	79
54	Identification and management of the woman at increased risk for breast cancer development. Breast Cancer Research and Treatment, 1994, 31, 53-60.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer, 1994, 73, 678-687.	2.0	398
56	Does transurethral resection of a clinically benign prostate gland increase the risk of developing clinical prostate cancer? A 10-year follow-up study. Cancer, 1994, 74, 2347-2351.	2.0	11
57	Colorectal cancer: detection, treatment, and rehabilitation. Ca-A Cancer Journal for Clinicians, 1994, 44, 27-42.	157.7	66
58	Atmospheric cosmic rays at aircraft altitudes. Environment International, 1994, 20, 645-663.	4.8	15
59	Receptivity of african-american men to prostate cancer screening. Urology, 1994, 43, 480-487.	0.5	64
60	Colon cancer detection: An algorithm using endoscopy and barium enema. Clinical Radiology, 1994, 49, 170-175.	0.5	18
61	Clinical and Economic Considerations in the Treatment of Prostate Cancer. Pharmacoeconomics, 1994, 6, 127-141.	1.7	11
62	Role of Androgens in Prostatic Cancer. Vitamins and Hormones, 1994, 49, 433-502.	0.7	120
63	Breast Cancer:. Journal of Women and Aging, 1994, 6, 151-164.	0.5	7
64	Cohort-Specific Risks of Developing Breast Cancer to Age 85 in Connecticut. Epidemiology, 1994, 5, 290-296.	1.2	11
65	Screening for prostate cancer: an analysis of the early experience. Ca-A Cancer Journal for Clinicians, 1995, 45, 134-147.	157.7	50
66	How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. Ca-A Cancer Journal for Clinicians, 1995, 45, 148-164.	157.7	34
67	Putting prophylactic mastectomy in proper perspective. Ca-A Cancer Journal for Clinicians, 1995, 45, 261-262.	157.7	6
68	The woman at increased risk for breast cancer: evaluation and management strategies. Ca-A Cancer Journal for Clinicians, 1995, 45, 263-278.	157.7	79
69	Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer?. Cancer, 1995, 75, 613-636.	2.0	112
70	Radiation protection in space. Acta Astronautica, 1995, 35, 313-338.	1.7	21
72	Prostate Cancer Screening. Surgical Oncology Clinics of North America, 1995, 4, 315-334.	0.6	2
73	Atypical mole syndrome: Risk factor for cutaneous malignant melanoma and implications for management. Journal of the American Academy of Dermatology, 1995, 32, 479-494.	0.6	114

#	Article	IF	Citations
74	The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffs. American Journal of Medicine, 1995, 99, 180-189.	0.6	19
75	Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? part I: Framing the debate. Urology, 1995, 46, 2-13.	0.5	33
76	Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Urology, 1995, 46, 445-461.	0.5	58
77	Detection of latent prostate cancer from routine screening: Comparison with breast cancer screening. Urology, 1995, 46, 533-537.	0.5	11
78	Can Nonsteroidal Anti-Inflammatory Drugs Be Recommended to Prevent Colon Cancer in High Risk Elderly Patients?. Drugs and Aging, 1995, 6, 421-425.	1.3	9
79	Presymptomatic Testing for Genetic Diseases of Later Life. Drugs and Aging, 1995, 7, 117-130.	1.3	3
80	Failure of Focal Prostate Cancer on Biopsy to Predict Focal Prostate Cancer: The Importance of Prevalence. Journal of Urology, 1995, 154, 1074-1077.	0.2	57
81	COST-EFFECTIVE PREOPERATIVE EVALUATION, OPERATIVE TREATMENT, AND POSTOPERATIVE FOLLOW-UP IN THE BREAST CANCER PATIENT. Surgical Clinics of North America, 1996, 76, 25-34.	0.5	17
82	EARLY-STAGE PROSTATE CANCER. Hematology/Oncology Clinics of North America, 1996, 10, 611-625.	0.9	9
83	Association of rectal prolapse with colorectal cancer. Surgery, 1996, 119, 51-55.	1.0	37
84	Barium enema: Colorectal polyps and carcinoma. Seminars in Roentgenology, 1996, 31, 125-141.	0.2	12
85	What are the benefits and costs of screening mammograms on Kentucky women aged 40–49?. , 1996, 63, 71-76.		0
86	Tumors in Bladder Remnant After Augmentation Enterocystoplasty. Journal of Urology, 1997, 157, 482-486.	0.2	90
87	Cancer Screening in the Older Patient. Clinics in Geriatric Medicine, 1997, 13, 97-118.	1.0	23
88	The natural history of clinical prostate carcinoma. Cancer, 1997, 80, 827-833.	2.0	39
89	123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. British Journal of Cancer, 1998, 78, 1-5.	2.9	28
90	Psychiatric morbidity in breast cancer — a review. Irish Journal of Medical Science, 1998, 167, 164-165.	0.8	0
91	Advances in radiology and the real versus apparent effects of early diagnosis. European Journal of Radiology, 1998, 27, 116-122.	1.2	38

#	Article	IF	Citations
92	BREAST DISEASE. Medical Clinics of North America, 1998, 82, 203-222.	1.1	7
93	Screening for Prostate Cancer - More Questions than Answers. Acta Oncológica, 1998, 37, 515-532.	0.8	9
94	Growth factor involvement in progression of prostate cancer. Clinical Chemistry, 1998, 44, 705-723.	1.5	191
95	Evolution of Isolated High-Grade Prostate Intraepithelial Neoplasia in a Mediterranean Patient Population. European Urology, 1999, 35, 496-497.	0.9	16
96	Helical CT colonography (virtual colonoscopy): the challenge that exists between advancing technology and generalizability American Journal of Roentgenology, 1999, 173, 549-559.	1.0	56
97	Treatment of metastatic breast cancer with continuous infusional 5 fluorouracil. Australian and New Zealand Journal of Medicine, 1999, 29, 517-522.	0.5	6
98	Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359. , 1999, 39, 234-239.		40
99	Fifty-Fifty=50%?. Journal of Behavioral Decision Making, 1999, 12, 149-163.	1.0	190
100	Epirubicin. Drugs and Aging, 1999, 15, 389-416.	1.3	62
101	Breast cancer screening, diagnosis, and treatment. Disease-a-Month, 1999, 45, 333-405.	0.4	6
102	Comparison of Risk Estimates for Selected Diseases and Causes of Death. Preventive Medicine, 1999, 28, 179-193.	1.6	35
103	Screening for prostate cancer. , 2000, 18, 29-36.		32
104	Treatment of prostate cancer: Watchful waiting, radical prostatectomy, and cryoablation., 2000, 18, 37-44.		25
105	Prevention of breast cancer. Critical Reviews in Oncology/Hematology, 2000, 33, 221-238.	2.0	7
106	Fenretinide Therapy in Prostate Cancer: Effects on Tissue and Serum Retinoid Concentration. Journal of Clinical Oncology, 2000, 18, 3804-3808.	0.8	25
107	THE PROSTATIC GLAND: MALIGNANCIES OTHER THAN ADENOCARCINOMAS. Radiologic Clinics of North America, 2000, 38, 179-202.	0.9	39
108	Surveillance Issues in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2001, 32, 99-105.	1.1	64
109	Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. International Journal of Cancer, 2001, 95, 260-265.	2.3	9

#	Article	IF	Citations
110	Inherent Dangers in Radiologic Screening. American Journal of Roentgenology, 2001, 177, 989-992.	1.0	31
111	Morphologic and Molecular Prognostic Markers in Prostate Cancer. Advances in Anatomic Pathology, 2002, 9, 115-128.	2.4	29
112	Experience with Methotrexate, 5-Fluorouracil, and Leucovorin (MFL): A First Line Effective, Minimally Toxic Regimen for Metastatic Breast Cancer. Cancer Investigation, 2002, 20, 24-28.	0.6	2
114	Localized prostate cancer. Current Problems in Surgery, 2002, 39, 843-957.	0.6	34
115	TRUS and Biopsy: Practical Aspects. European Urology, 2002, 41, I-X.	0.9	4
116	Colorectal carcinoma in poor blacks. Cancer, 2002, 94, 2327-2332.	2.0	38
118	National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology, 2003, 61, 14-24.	0.5	152
119	Memories of colonoscopy: a randomized trial. Pain, 2003, 104, 187-194.	2.0	350
120	Prognostic Factors in Prostate Cancer. Pathology Patterns Reviews, 2003, 120, S85-S100.	0.4	19
121	A research on the level of urine neopterin to see if it may provide a vital clue for a provisional diagnosis of breast cancer in menopausal women. Maturitas, 2004, 48, 432-437.	1.0	10
122	Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. European Journal of Cancer, 2004, 40, 84-89.	1.3	63
123	Prostatic Adenocarcinoma Metastasis in the Thyroid Gland. Endocrine Journal, 2004, 51, 445-448.	0.7	20
124	Mechanisms and markers of carcinogenesis and neoplastic progression. Expert Opinion on Biological Therapy, 2005, 5, 1317-1332.	1.4	5
125	Age-associated Iron Accumulation in Bone: Implications for Postmenopausal Osteoporosis and a New Target for Prevention and Treatment by Chelation. BioMetals, 2006, 19, 245-251.	1.8	42
126	Computed tomography and magnetic resonance colonography. Radiology and Oncology, 2007, 41, 1-12.	0.6	1
127	Prostate-Specific Antigen Levels, Prostate-Specific Antigen Kinetics, and Prostate Cancer Prognosis: A Tocsin Calling for Prospective Studies. Journal of the National Cancer Institute, 2007, 99, 496-497.	3.0	11
128	The Challenge of Managing Prostate Cancer. American Journal of Roentgenology, 2007, 188, 1-1.	1.0	46
130	Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/ml undergoing radical cystoprostatectomy for bladder cancer in iranian men. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2007, 33, 167-175.	0.7	23

#	Article	IF	CITATIONS
131	Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detection and Prevention, 2007, 31, 59-63.	2.1	45
132	Cumulative diagnostic radiation exposure in children with ventriculoperitoneal shunts. Child's Nervous System, 2008, 24, 505-506.	0.6	0
133	Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer, 2008, 113, 286-292.	2.0	70
134	Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 1685.	3.8	464
135	Why Are a High Overdiagnosis Probability and a Long Lead Time for Prostate Cancer Screening So Important?. Journal of the National Cancer Institute, 2009, 101, 362-363.	3.0	25
136	Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opinion on Therapeutic Targets, 2009, 13, 1449-1458.	1.5	70
137	Prostate Cancer: Current Evidence Weighs Against Population Screening. Ca-A Cancer Journal for Clinicians, 2009, 59, 220-224.	157.7	47
138	Chemoprevention of Prostate Cancer. Journal of Urology, 2009, 182, 499-508.	0.2	80
139	DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening. Current Molecular Medicine, 2010, 10, 123-132.	0.6	98
140	Randomized trial results did not resolve controversies surrounding prostate cancer screening. Current Opinion in Urology, 2010, 20, 189-193.	0.9	11
141	Risks of premature death from smoking in 15â€yearâ€old Australians. Australian Journal of Public Health, 1993, 17, 358-364.	0.2	11
142	Does the Benefit Justify the Risk?. Journal of the National Cancer Institute, 2010, 102, 4-5.	3.0	1
143	Prostate-Specific Antigen, Risk Factors, and Prostate Cancer: Confounders Nestled in an Enigma. Journal of the National Cancer Institute, 2010, 102, 1299-1301.	3.0	5
144	Screening for Prostate Cancer. New England Journal of Medicine, 2011, 365, 2013-2019.	13.9	183
145	The Prostate Cancer Risk Calculator From the Prostate Cancer Prevention Trial Underestimates the Risk of High Grade Cancer in Contemporary Referral Patients. Journal of Urology, 2011, 185, 483-488.	0.2	18
146	The Expression and Clinical Significance of GTP-Binding RAS-Like 3 <i>(ARHI)</i> and MicroRNA 221 and 222 in Prostate Cancer. Journal of International Medical Research, 2011, 39, 1870-1875.	0.4	35
147	Is sampling transitional zone in patients who had prior negative prostate biopsy necessary?. International Urology and Nephrology, 2012, 44, 1071-1075.	0.6	2
148	Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health, 2012, 12, 992.	1.2	88

#	Article	IF	CITATIONS
149	Simultaneous and combined detection of multiple tumor biomarkers for prostate cancer in human serum by suspension array technology. Biosensors and Bioelectronics, 2013, 47, 92-98.	5.3	40
150	Synchronous primary malignancies of the male urogenital tract. Canadian Urological Association Journal, 2014, 8, 353.	0.3	6
152	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
153	The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. Journal of Urology, 2016, 195, 1403-1408.	0.2	24
154	Fluorescence-encoded polystyrene microspheres for the application of suspension array technology. , 2019, , 221-267.		0
155	A Risk Assessment Tool for Predicting Fragility Fractures and Mortality in the Elderly. Journal of Bone and Mineral Research, 2020, 35, 1923-1934.	3.1	10
156	A Novel Method for Cancer Subtyping and Risk Prediction Using Consensus Factor Analysis. Frontiers in Oncology, 2020, 10, 1052.	1.3	13
157	Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 1993, 71, 933-938.	2.0	478
158	Prostatic Cancer: An Age-Old Problem. Advances in Experimental Medicine and Biology, 1993, 330, 167-184.	0.8	7
159	Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells., 1991,, 51-63.		25
160	Daughters of Breast Cancer Patients. , 1998, , 603-619.		3
161	Quantitative Approaches to Clinical Diagnosis of Cancer in Elderly Patients. Clinics in Geriatric Medicine, 1987, 3, 447-461.	1.0	2
162	Tumors in Bladder Remnant After Augmentation Enterocystoplasty. Journal of Urology, 1997, , 482-486.	0.2	1
163	CT and MR Colonography: Scanning Techniques, Postprocessing, and Emphasis on Polyp Detection. Radiographics, 2004, 24, e18-e18.	1.4	34
164	Association between Levels of Serum Ferritin and Bone Mineral Density in Korean Premenopausal and Postmenopausal Women: KNHANES 2008–2010. PLoS ONE, 2014, 9, e114972.	1.1	20
165	Prostate Cancer Elder Alert. Journal of Gerontological Nursing, 2000, 26, 6-9.	0.3	4
166	Association between single nucleotide polymorphisms on chromosome 17q and the risk of prostate cancer in a Chinese population. Chinese Journal of Cancer, 2011, 30, 721-730.	4.9	9
167	Peptide Imaging. , 2000, , 135-158.		1

#	Article	IF	CITATIONS
168	Clinical Assessment of 324 Breast Cancer Cases in Two Centers Between the Years of 1992 and 2002. Acta Medica (Hradec Kralove), 2003, 46, 195-199.	0.2	0
169	Anatomic Radical Prostatectomy in the Management of Localized Prostate Cancer., 2004, , 1-62.		O
171	Diagnostic Value of Transrectal Ultrasonography In Patients With PSA Values >20 ng/ml PSA değeri 20 ng/ml Üzerindeki Hastalarda Transrektal Ultrasonografi nin Tanı Değeri. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 2007, 60, 1.	0.0	0
172	Breast-Cancer Prevention with Antiestrogens. , 2009, , 213-231.		0
173	Epidemiology of Breast Cancer. , 2011, , 25-55.		3
174	Natural History of Mammary Tumors Seen in a Breast Center. , 1987, , 29-37.		0
175	Neoplastic Diseases., 1992,, 945-992.		0
176	Benign and Malignant Prostatic Neoplasms: Human Studies. , 1994, 49, 293-331.		7
177	Cancers of the Urinary Tract., 1998,, 695-722.		1
180	Peptide Imaging. , 2006, , 153-184.		0
181	Screening for prostate cancer. Western Journal of Medicine, 1995, 162, 235-42.	0.3	3
182	More on the prostate cancer screening controversy. Western Journal of Medicine, 1995, 163, 183.	0.3	0
183	Factors associated with obtaining health screening among women of reproductive age. Public Health Reports, 1993, 108, 76-86.	1.3	42
184	Cancer screening intervention among black women in inner-city Atlanta-design of a study. Public Health Reports, 1992, 107, 381-8.	1.3	23
185	Risks and probabilities of breast cancer: short-term versus lifetime probabilities. Cmaj, 1994, 150, 211-6.	0.9	10
186	Hereditary aspects of prostate cancer. Cmaj, 1995, 153, 895-900.	0.9	3
187	Colorectal cancer. Can we lower the death rate in the 1990s?. Canadian Family Physician, 1993, 39, 107-14.	0.1	6
188	Head and neck cancer in blacks. Journal of the National Medical Association, 1994, 86, 530-4.	0.6	11

# ARTICLE IF CITATIONS

195 Hormonal Therapies in Cancers. Cancer Treatment and Research, 2023, , 91-104. 0.2 0